<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002085</url>
  </required_header>
  <id_info>
    <org_study_id>058D</org_study_id>
    <secondary_id>066-169</secondary_id>
    <nct_id>NCT00002085</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy</brief_title>
  <official_title>A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of azithromycin given chronically for the treatment of&#xD;
      serious nontuberculous mycobacterial infection in patients failing or intolerant of other&#xD;
      available therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Mycobacterium Avium-Intracellulare Infection</condition>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis, Mycobacterium Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Other antimicrobial drugs as long as documented on Case Report Form.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Serious nontuberculous mycobacterial infection.&#xD;
&#xD;
          -  Approval of eligibility from Pfizer Clinical Monitor. Patients below the legal age of&#xD;
             consent must have consent of parent or guardian.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Pregnant women, women of childbearing potential, and children will not be specifically&#xD;
             excluded from participation. However, patients and physicians should be aware that the&#xD;
             safety of azithromycin during pregnancy and in long-term use in children and adults&#xD;
             has not been established. The risks and benefits of azithromycin use in these patients&#xD;
             will be considered in consultation with the physician and the Pfizer Clinical Monitor.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Disseminated Mycobacterium avium complex (MAC) who are eligible for treatment with&#xD;
             azithromycin under protocol 066-162.&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to macrolide antibiotics.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        History of hypersensitivity or intolerance to azithromycin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Day</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pfizer Central Research</name>
      <address>
        <city>Groton</city>
        <state>Connecticut</state>
        <zip>06340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natl Cancer Institute / Metabolism Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1998</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Mycobacterium avium-intracellulare Infection</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Mycobacterium Infections, Atypical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

